The role of PD-1 and PD-L1 in patients with coronary artery disease
Project/Area Number |
19K17570
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 53020:Cardiology-related
|
Research Institution | Kumamoto University |
Principal Investigator |
Fujisue Koichiro 熊本大学, 大学院生命科学研究部(医), 助教 (10779151)
|
Project Period (FY) |
2019-04-01 – 2023-03-31
|
Project Status |
Completed (Fiscal Year 2022)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 急性冠症候群 / 免疫チェックポイントタンパク / 動脈硬化 / 冠動脈疾患 / PD-L1 / PD-1 / 血管内皮機能 |
Outline of Research at the Start |
冠動脈疾患患者において次の項目と血球のPD-1、PD-L1発現および血清中の可溶性PD-1、PD-L1値との関連性を調べる ①冠動脈病変の重症度を表すSYNTAX scoreやGensini score ②冠動脈血管内超音波(IVUS)で評価した冠動脈プラーク容積 ③炎症マーカーと炎症性サイトカインの血中濃度 ④非侵襲的末梢血管内皮機能検査であるReactive hyperemia peripheral artery tonometry (RH-PAT)で評価した血管内皮機能
|
Outline of Final Research Achievements |
The immune system is involved in coronary artery disease, but the role of immune checkpoint proteins, Programmed death-1 (PD-1) and Programmed death-ligand 1 (PD-L1), that regulate these mechanisms in coronary artery disease is unknown. In this study, we investigated the involvement of PD-1 and PD-L1 in coronary artery disease. Patients with acute coronary syndrome had higher levels of serum PD-L1 than those with chronic coronary syndrome. In addition, patients with coronary artery disease who had higher levels of sPD-L1 had a higher incidence of cardiovascular events than those with lower levels of sPD-L1. These results suggest that PD-1 and PD-L1 can be novel markers and prognostic factors in patients with coronary artery disease.
|
Academic Significance and Societal Importance of the Research Achievements |
近年、PD-1やPD-L1は悪性疾患の病態、治療において注目されている分子であるが、動脈硬化においてもその病態に炎症が深く関わっており、特に急性冠症候群の発症に密接な関連がある。急性冠症候群の病態にPD-1、 PD-L1が何らかの役割を担っている可能性があるが未だ解明されていなかった。 本研究結果からPD-1, PD-L1の冠動脈疾患における病態や予後との関連性が明らかとなり、新たなバイオマーカーになりうるとともに、新たな治療ターゲットとなる可能性がある。
|
Report
(5 results)
Research Products
(8 results)
-
-
-
[Presentation] Soluble Programed Cell Death Ligand-1 is Associated with Future Heart Failure Hospitalization in Patients with Atherosclerotic Cardiovascular Disease.2023
Author(s)
Atsushi Nozuhara, Koichiro Fujisue, Kenshi Yamanaga, Eiichiro Yamamoto, Koichi Egashira, Takashi Komorita, Daisuke Sueta, Hiroki Usuku, Satoshi Araki, Seiji Takashio, Kenichi Matsushita, Kenichi Tsujita
Organizer
第87回日本循環器学会総会・学術集会2023
Related Report
-
[Presentation] Soluble programed cell death ligand-1 is associated with future heart failure hospitalization in patients with atherosclerotic cardiovascular disease.2022
Author(s)
6.Nozuhara A, Miyazaki S, Fujisue K, Yamanaga K, Yamamoto E, Egashira K, Komorita T, Sueta D, Usuku H, Araki S, Takashio S, Matsushita K, Tsujita K.
Organizer
American Heart Association Scientific Sessions 2022
Related Report
Int'l Joint Research
-
[Presentation] Increased Soluble Programed Cell Death Ligand-1 is Associated with Acute Coronary Syndrome.2021
Author(s)
Fujisue K, Miyazaki S, Komorita T, Egashira K, Yamamoto E, Sueta D, Oike F, Usuku H, Takashio S, Araki S, Matsushita K, Tsujita K.
Organizer
American Heart Association Scientific Sessions 2021
Related Report
Int'l Joint Research
-
[Presentation] Prognostic Significance of Soluble Programed Cell Death Ligand-1 on Cardiovascular Outcomes in Patients with Atherosclerotic Cardiovascular Dsease.2021
Author(s)
Miyazaki S, Fujisue K, Yamanaga K, Yamamoto E, Egashira K, Komorita T, Sueta D, Usuku H, Araki S, Takasiho S, Matsushita K, Tsujita K.
Organizer
American Heart Association Scientific Sessions 2021
Related Report
Int'l Joint Research
-
-